Serum/glucocorticoid regulated kinase 1 (SGK1) in neurological disorders: pain or gain

May combine two claims.

Inhibiting SGK activity completely nullifies effects of neutrophil survival factors, leading to delayed resolution of inflammation, but does not alter neutrophil recruitment to sites of inflammation.

“Inhibiting SGK activity completely nullifies the effects of neutrophil survival factors, leading to a delayed resolution of inflammation. However, this does not alter the recruitment of neutrophils to sites of inflammation within the body”

• cites Burgon et al., 2014 sourceDisputed

  The Results report that SGK1 inhibition increased, rather than delayed, inflammation resolution (genetic inhibition section; page unavailable). They also report that inhibition blocked survival induced by GM-CSF and hypoxia, but not by LPS or ATPγs (human neutrophil survival section). Recruitment was unchanged after genetic knockdown, although the inhibitor GSK650394 reduced it through apparent off-target effects. (LLM, conf=0.92)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

SGK1 impacts blood pressure regulation, with significant effect within the blood-brain barrier.

“SGK1 impacts blood pressure regulation. This effect is significant within the blood-brain barrier”

• cites Faresse et al., 2012 sourceNot checked — no full text of the source
• cites Klug et al., 2021 sourcePartly supported

  The Discussion reports that SGK1 contributes to high-glucose-induced changes in ion transport in blood-brain barrier endothelial cells. It does not report an effect on blood pressure regulation; searches for blood pressure and hypertension found no such finding in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites Zhang et al., 2022aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

Alternative translation initiation from seven conserved in-frame methionine codons in the N-terminus produces four distinct SGK1 isoforms.

“One study analyzing mouse SGK1 cDNA reports the conservation of seven in-frame methionine codons (ATG) in the N-terminus across various vertebrates, including humans, mice, frogs, and sharks (Arteaga et al., 2007). Alternative translation initiation from these conserved codons in the N-terminus produces four distinct SGK1 isoforms”

• cites Arteaga et al., 2007 sourcePartly supported

  The section “Alternative Translation Initiation Produces Four Sgk1 Isoforms” reports seven in-frame methionine codons in mouse Sgk1 and four isoforms produced by alternative initiation. But Table 1 shows that not all seven codons are conserved across the listed vertebrates, and the section “Endogenous Sgk1 in Mouse Cells and in Tissues Expresses as Several Isoforms” reports at least three isoforms for human and frog Sgk1, not four. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

SGK1 influences cell growth, proliferation, survival, migration, and apoptosis.

“Moreover, it significantly influences cell growth, proliferation, survival, migration, and apoptosis”

• cites Amato et al., 2009 sourceNot checked — no full text of the source
• cites Bai et al., 2015 sourceSupported
• cites Lang et al., 2010aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Activation of SGK1 involves mTORC2 phosphorylating Ser422, followed by PDK1 transferring phosphate to Thr256, which phosphorylates the activation loop and enlarges the ATP-binding site.

“In the activation process of SGK1, extracellular stimuli induce the activation of mTORC2, which phosphorylates Ser422 on SGK1’s hydrophobic motif (Garcia-Martinez and Alessi, 2008). Subsequently, 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) is recruited to the phosphorylated Ser, leading to the transfer of a phosphate group to Thr256 within the kinase domain of SGK1 (Biondi et al., 2001),”

• cites Garcia-Martinez and Alessi, 2008 sourceSupported
• cites Biondi et al., 2001 sourceSupported
• cites Akhoon et al., 2019 sourceNot checked — no full text of the source

May combine two claims.

Activated SGK1 rapidly stimulates ENaC, enhancing the driving force for secretion of other ion transport such as potassium.

“The activated SGK1 then rapidly stimulates the ENaC, enhancing the driving force for the secretion of other ion transport, such as potassium (K+)”

• cites Saha et al., 2022 sourceSupported

May combine two claims.

WNK1 interacts with chloride ions to alter its conformation, facilitating capture of SGK1, promoting mTORC2-SGK1 interaction and SGK1 phosphorylation while inhibiting WNK1 kinase activity.

“Additionally, WNK1 interacts with chloride ions (Cl−) to alter its conformation, facilitating the capture of SGK1 (Piala et al., 2014; Terker et al., 2015). This conformational change promotes the interaction between Mammalian Target of Rapamycin Complex 2 (mTORC2) and SGK1 and enhances the phosphorylation of SGK1 while simultaneously inhibiting the kinase activity of WNK1.”

• cites Piala et al., 2014 sourcePartly supported

  The Abstract and Results report that chloride binds WNK1, stabilizes its inactive conformation, and inhibits its autophosphorylation and activation. The Introduction mentions that WNK1 activates SGK1, but our copy does not support the claimed chloride-dependent capture of SGK1, increased mTORC2–SGK1 interaction, or enhanced SGK1 phosphorylation. No page numbers are available in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites Terker et al., 2015 sourcePartly supported

  The Introduction and Results section on extracellular potassium and WNK kinases report that chloride binds WNK1 and inhibits its activation, and test mutations at its chloride-binding sites. The cited paper does not describe a chloride-induced conformational change that captures SGK1, promotes mTORC2–SGK1 interaction, or enhances SGK1 phosphorylation. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

SGK1 is a serine/threonine kinase that is extensively expressed in most tissues.

“Serum/Glucocorticoid Regulated Kinase 1 (SGK1), a member of the AGC kinase family (cAMP-dependent, cGMP-dependent, and protein kinase C), is a serine/threonine kinase that exhibits extensive expression in a majority of tissues”

• cites Waldegger et al., 1997 sourcePartly supported

  The Discussion says h-sgk transcripts were expressed in all human tissues analyzed, supporting widespread expression. It describes h-sgk as encoding a *putative* serine/threonine protein kinase, so the unqualified kinase characterization is stronger than this paper establishes. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites Webster et al., 1993 sourcePartly supported

  The paper describes sgk as a member of the serine/threonine protein kinase gene family and reports that its mRNA is expressed in most adult rat tissues (opening summary; page not provided). The claim broadens that finding to SGK1 expression in most tissues generally, whereas the cited evidence concerns mRNA in adult rats. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

SGK1 possesses a kinase domain with a pocket that recognizes hydrophobic motifs containing phosphoserine/phosphothreonine, enabling distinct substrate affinity.

“Similar to other AGC protein kinases, SGK1 possesses a kinase domain featuring a pocket that recognizes hydrophobic motifs containing phosphoserine/phosphothreonine. This pocket achieves recognition through phosphorylation of two oppositely positioned arginine and lysine residues. This structural characteristic enables SGK1’s distinct substrate affinity in biological processes”

• cites Frodin et al., 2002 sourcePartly supported

  The Abstract and Introduction state that SGK1 has a phosphate-binding pocket that interacts with its own phosphorylated hydrophobic motif and stimulates kinase activity. The Discussion says oppositely positioned arginine or lysine residues bind the motif’s phosphate; it does not say those residues are phosphorylated. These passages do not establish the claimed distinct substrate affinity. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

May combine two claims.

Astrocytes play a signaling hub in stress-induced changes in brain glucose metabolism, with SGK1 being a factor in formation of aversive memories.

“It’s noteworthy that astrocytes play a signaling hub in stress-induced changes in brain glucose metabolism, with SGK1 being a factor in formation of aversive memories”

• cites Tertil et al., 2018 sourcePartly supported

  The Abstract and Results identify astrocytes as important for glucocorticoid-dependent aversive memory and show that SGK1 regulates glucose uptake in astrocytes. The Discussion proposes that this pathway may affect stress-induced memory formation, but does not establish SGK1 itself as a factor in aversive memory formation. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

LTP in the hippocampus is closely associated with phosphorylation of SGK1 at Ser422; dominant-negative SGK1 targeting Ser422 disrupts LTP with regional specificity.

“LTP in the hippocampus is closely associated with the phosphorylation of SGK1 at Ser422. Introducing a dominant-negative SGK1 targeting Ser422, disrupts LTP with regional specificity in the brain”

• cites Ma et al., 2006Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Steffke et al., 2020 sourcePartly supported

  The Introduction (page unavailable) reports increased SGK1 phosphorylation at Ser422 after protocols that induce hippocampal LTP, and says SGK1 inhibition impairs LTP expression but not induction. It does not report that a Ser422-targeting dominant-negative SGK1 disrupts LTP with regional specificity. The Results concern region-dependent dendritic spine changes, while the Discussion says regional effects on synaptic function and plasticity remain to be tested. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

SGK1 acts as an effective negative regulator in TLR-induced inflammation; pharmacological inhibition or siRNA of SGK1 enhances production of pro-inflammatory cytokines TNF, IL-12, and IL-6 in monocytes bound to TLR.

“In contrast, SGK1 acts as an effective negative regulator in TLR-induced inflammation. Pharmacological inhibition or suppression using small interfering RNA (siRNA) of SGK1 enhances the production of pro-inflammatory cytokines (such as TNF, IL-12, and IL-6) in monocytes bound to TLR”

• cites Zhou et al., 2015 sourceSupported

May combine two claims.

In the dentate gyrus, increased SGK1 activity promotes maturation of dendritic spines, but the effect is opposite in the CA1 region.

“In the dentate gyrus, increased SGK1 activity promotes the maturation of dendritic spines. However, the effect is opposite in the CA1 region”

• cites Steffke et al., 2020 sourceSupported

May combine two claims.

SGK1 increases neuronal plasticity by modulating SRF and CREB1, allowing transition of stored information from short-term to long-term memories.

“Specifically, SGK1 increases neuronal plasticity by modulating the activity of transcription factors SRF and CREB1. This process allows transitioning stored information from short-term memories to long-term memories”

• cites Gonzalez et al., 2019 sourceCould not verify

  The Introduction (page not available) discusses Zif268 and object-recognition memory reconsolidation, not SGK1. Searches for SGK1, SRF, CREB1, and short-term-to-long-term memory transition found no passage in our copy addressing the attributed mechanism. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites Tyan et al., 2008 sourceNot checked — no full text of the source

May combine two claims.

Pathological states differ significantly across neurological diseases, and alterations in SGK1 vary, leading to distinct impacts of SGK1 on different diseases; even within the same disease, SGK1's influence on progression can vary.

“However, the pathological states differ significantly across various neurological diseases, and the alterations in SGK1 also vary, leading to distinct impacts of SGK1 on different diseases. Even within the same disease, the influence of SGK1 on its progression can vary”

• cites Elahi et al., 2021 sourcePartly supported

  The Results (page unavailable) show that SGK1 overexpression worsened tau pathology and memory in Tg601 mice. The References list a study reporting improved memory and amyloid pathology with SGK1 overexpression in a different Alzheimer’s mouse model, offering some support for variation within one disease. This paper does not establish that differing pathological states and SGK1 alterations cause distinct effects across neurological diseases. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites Lian et al., 2020 sourceNot checked — no full text of the source

May combine two claims.

NDRG1 is activated during myelination in developmental stages and in remyelination following myelin damage in adult mice.

“Interestingly, NDRG1 is activated during myelination in developmental stages and in the remyelination process following myelin damage in adult mice”

• cites Marechal et al., 2022 sourceSupported

May combine two claims.

Interaction of SGK1, GSK-3β, and Tau leads to formation of an SGK1-GSK-3β-Tau complex, contributing to abnormal Tau tangles and disintegrating microtubules in neurons.

“Interaction of these proteins lead to the formation of an SGK1-GSK-3β-Tau complex, contributing to abnormal Tau tangles and ultimately resulting in disintegrating microtubules in neurons”

• cites Elahi et al., 2021 sourcePartly supported

  The Results section ('SGK1-mediated tau phosphorylation at Ser214 and GSK-3ß activation'; page unavailable) describes a scaffold-like SGK1–GSK-3β–tau complex and increased tau aggregation and fibril formation. It reports reduced tubulin polymerization activity, but does not show that the complex causes neurofibrillary tangles or disintegrating microtubules in neurons. The Discussion says SGK1 might disassemble microtubules, rather than establishing that outcome. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites Sayas and Avila, 2021 sourcePartly supported

  Section 3 reports a tau–GSK-3β complex and links tau phosphorylation to reduced microtubule binding and neurofibrillary tangles. It does not identify SGK1 as part of that complex or establish the claimed sequence ending in disintegrating neuronal microtubules (searched for SGK1 and the three-protein complex). (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Knockdown of SGK1 in SH-SY5Y cells using siRNA causes downregulation of dopaminergic cells and upregulation of α-syn expression.

“Upon the knockdown of SGK1 in SH-SY5Y cells using siRNA, a downregulation of dopaminergic cells and an upregulation of α-syn expression were observed”

• cites Yeo et al., 2018 sourceSupported

May combine two claims.

SGK1 is a stress-responsive kinase typically upregulated in cells undergoing stress or damage.

“Mechanistically, SGK1 is a stress-responsive kinase, typically upregulated in cells undergoing stress or damage”

• cites Dattilo et al., 2020 sourceSupported

May combine two claims.

Pharmacological inhibition and silencing of SGK1 ameliorate pathological synuclein aggregation and PD-related behavioral deficits in various in vitro and in vivo MPTP-induced PD models, and protect midbrain dopaminergic neurons from degeneration.

“Pharmacological inhibition and silencing of SGK1 can ameliorate pathological synuclein aggregation and PD-related behavioral deficits in various in vitro and in vivo MPTP-induced PD models. Moreover, this intervention protects midbrain dopaminergic neurons from degeneration”

• cites Kwon et al., 2021 sourcePartly supported

  The Results report that SGK1 inhibition or silencing reduced synuclein pathology and protected midbrain dopamine neurons across PD models; inhibitor treatment also improved behavioral deficits in MPTP-treated mice. However, the Methods distinguish the MPTP mouse model from the synuclein-induced model, and the Results describe the aggregation experiments in synuclein-based models—not as various in vitro and in vivo MPTP-induced models. Page numbers are unavailable in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

• AssumptionRests on an assumption: The effects of pharmacological inhibitors or siRNA against SGK1 are due to specific modulation of SGK1 rather than off-target effects.

May combine two claims.

SGK1 maintains stable levels of BACE1 and Cofilin, indicating its influence does not involve promoting the amyloidogenic β pathway.

“Simultaneously, SGK1 maintains stable levels of BACE1 (β-secretase) and Cofilin, indicating its influence does not involve promoting the amyloidogenic β pathway”

• cites Hampel et al., 2021 sourceCould not verify

  The Amyloidogenesis section identifies BACE1 as the β-secretase involved in Aβ production, but does not address SGK1’s effect on that pathway. Searches for SGK1 and Cofilin found no passage reporting stable levels of either protein or drawing the claimed conclusion about SGK1. Page numbers were unavailable in our copy. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites Lian et al., 2020 sourceNot checked — no full text of the source

May combine two claims.

SGK1 may promote expression or activity of ADAM10 and IDE, enhancing APP metabolism through the non-amyloidogenic pathway and increasing Aβ degradation.

“This finding suggests SGK1 may promote the expression or activity of ADAM10 and IDE, thereby enhancing the metabolism of APP through the non-amyloidogenic β pathway and increasing the degradation of Aβ”

• cites Lauer et al., 2020 sourcePartly supported

  The Abstract and Discussion report that APP intracellular domain (AICD) promotes IDE expression and IDE-mediated Aβ degradation. They do not identify SGK1 or ADAM10 as drivers of those effects. The Introduction also describes non-amyloidogenic APP processing as an α- and γ-secretase pathway, not the β pathway printed in the citing sentence. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

SGK1-related pathways regulate IL-6 expression in astrocytes, mitigating loss of oligodendrocyte progenitor cells (OPCs).

“SGK1-related pathways regulate IL-6 expression in astrocytes, mitigating the loss of oligodendrocyte progenitor cells (OPCs)”

• cites Gao et al., 2022 sourceSupported

May combine two claims.

Despite elevated myelin formation in AD mice, overall myelin levels are reduced, suggesting increased myelin regeneration is insufficient to counterbalance accelerated myelin degeneration.

“Despite the elevated rate of myelin formation in AD mice, the overall myelin levels were reduced, suggesting the increased rate of myelin regeneration is insufficient to fully counterbalance the accelerated myelin degeneration”

• cites Chen et al., 2021aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Zou et al., 2023 sourceSupported

May combine two claims.

In 3NP-treated mouse models, SGK1 expression levels rose 2.7-fold compared to controls, but treatment with cannabigerol resulted in a 1.41-fold decrease in SGK1 expression.

“In 3NP-treated mouse models, SGK1 expression levels rose 2.7-fold compared to controls, but treatment with cannabigerol resulted in a 1.41-fold decrease in SGK1 expression”

• cites Valdeolivas et al., 2015 sourceSupported

May combine two claims.

Beneficial effects of SGK1 inhibition may be related to enhancement of neuroglial activity, aiding clearance of glutamate toxicity and preventing neuroglial cell senescence and mitochondrial damage.

“The beneficial effects of SGK1 inhibition may be related to its enhancement of neuroglial activity, which aids in the clearance of glutamate toxicity and prevents neuroglial cell senescence and mitochondrial damage”

• cites Kwon et al., 2021 sourceSupported

May combine two claims.

In peripheral colonic tissues of PD groups, SGK1 expression is notably decreased alongside increased α-syn expression; suppressing SGK1 expression exacerbates expression of genes associated with PD-related constipation.

“In the peripheral colonic tissues of PD groups, there is a notable decrease in the expression of SGK1, alongside an increase in α-syn expression. Additionally, suppressing SGK1 expression exacerbates the expression of genes associated with PD-related constipation”

• cites Seo et al., 2023 sourcePartly supported

  The Discussion (§3) reports decreased SGK1 and increased α-syn in the colon of MPTP-induced PD mice. Results (§2.4) report that SGK1 knockdown in SW480 cells increased α-syn and Na+/K+ pump ATPase α1 expression, but the paper presents their connection to constipation as an inference, not a demonstrated exacerbation of constipation-related gene expression. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

Overexpression of SGK1 in cells enhances mitochondrial function and inactivates GSK3β, MKK4, and JNK, protecting cells from oxidative stress-induced damage.

“Additionally, overexpression of SGK1 in cells enhances mitochondrial function and inactivates GSK3β, MKK4, and JNK, protecting cells from oxidative stress-induced damage”

• cites Iqbal et al., 2015 sourceNot checked — no full text of the source
• cites Jiang et al., 2019 sourcePartly supported

  Results §3.5 and the Discussion link SGK1 to mitochondrial function, GSK3β inactivation, and protection of H2O2-exposed HK-2 renal cells. The paper does not support the added claim that SGK1 inactivates MKK4 or JNK; its experiments also examine SGK1 knockdown rather than experimentally induced overexpression. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

SGK1 is related to Akt, activated by PI3K, and involved in mediating survival signals.

“SGK1, related to Akt and activated by PI3K, is also involved in mediating survival signals”

• cites Brunet et al., 2001 sourceSupported

May combine two claims.

After TBI, loss of myelination can trigger neuroinflammation and upregulation of SGK1 transcription levels in oligodendrocytes.

“After TBI, the loss of myelination can trigger neuroinflammation and upregulation of SGK1 transcription levels in oligodendrocytes”

• cites Imaizumi et al., 1994 sourceNot checked — no full text of the source
• cites Kempuraj et al., 2021 sourcePartly supported

  The Discussion (page unavailable) says TBI-related brain damage can lead to neuroinflammatory responses. It does not say that loss of myelination triggers those responses, or report increased SGK1 transcription in oligodendrocytes; searches for SGK1 and myelination found no supporting passage. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

SGK1 facilitates M2 microglial polarization and aids in reducing post-ischemic microglial proliferation, diminishing neuroinflammation by activating SGK1-CREB-FOXO3a pathway.

“SGK1 facilitates M2 microglial polarization and aids in reducing post-ischemic microglial proliferation, diminishing neuroinflammation by activating the SGK1-CREB-FOXO3a pathway”

• cites Chen et al., 2023 sourcePartly supported

  The Results (p. 11) report that Swell1 overexpression promotes M2 microglial polarization and reduces inflammatory factors after ischemic stroke. But the Discussion (p. 16) says Swell1 promotes—not reduces—resident microglial proliferation through the SGK1–CREB–FOXO3a pathway. The claim reverses that proliferation finding and attributes the broader effects to SGK1 alone rather than Swell1 activation. (LLM, conf=0.89)

  Experimental — accuracy not yet measured

May combine two claims.

Post-MCAO, SGK1 levels initially double compared to sham-operated rats at 6 hours before falling below control levels after 24 hours, accompanied by an increase in neuronal apoptosis.

“post-MCAO, the levels initially double compared to sham-operated rats at 6 hours before falling below control levels after 24 hours, accompanied by an increase in neuronal apoptosis”

• cites Nishida et al., 2004 sourceNot checked — no full text of the source
• cites Zhang et al., 2014 sourcePartly supported

  The discussion (page unavailable) reports that SGK1 levels rose transiently after MCAO and returned to control levels by 24 hours; it does not report that they fell below control. Figure 5 identifies a 6-hour measurement, but the supplied text does not establish a doubling at that time. The Results section reports increasing TUNEL-positive cells after reperfusion, supporting the apoptosis portion. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

In rat hippocampal neurons, SGK1 levels significantly drop following OGD and further decline over time.

“In rat hippocampal neurons, SGK1 levels significantly drop following OGD and further decline over time”

• cites Nishida et al., 2004 sourceNot checked — no full text of the source
• cites Zhang et al., 2014 sourceSupported

May combine two claims.

SGK1 plays a critical role in VEGF-mediated angiogenesis, which plays a role in both stress-induced BBB dysfunction and development of depressive-like behaviors.

“This finding underscores the critical role of SGK1 in VEGF-mediated angiogenesis, which plays a role in both stress-induced BBB dysfunction and the development of depressive-like behaviors”

• cites Matsuno et al., 2022 sourcePartly supported

  The Abstract reports that VEGF/VEGFR2 contributes to stress-induced BBB permeability and depressive-like behavior in chronically stressed mice, and describes VEGF as a mediator of angiogenesis. It does not mention SGK1 or establish that SGK1 is critical to VEGF-mediated angiogenesis; nor does it show that angiogenesis itself causes the reported BBB and behavioral effects. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Activation of SGK1 can increase cytoplasmic calcium levels, thereby compromising integrity of BBB.

“activation of SGK1, which can increase cytoplasmic calcium levels, thereby compromising the integrity of the BBB”

• cites Brown et al., 2008 sourcePartly supported

  The Conclusions (page unavailable) say that TRPC and TRPV channels mediate calcium influx at the BBB and may modulate barrier integrity. The Discussion (page unavailable) also links increased intracellular calcium and altered barrier permeability. Our copy does not identify SGK1 as the activator or establish that activating it compromises the BBB; searches for SGK1 and serum glucocorticoid-regulated kinase found no supporting passage. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites Imai et al., 2003 sourceNot checked — no full text of the source

May combine two claims.

SGK1-knockdown leads to increased infarct size and brain edema, promotes neuronal apoptosis, and reduces Nissl bodies in rat MCAO model.

“SGK1-knockdow leads to increased infarct size and brain edema, promotes neuronal apoptosis, and reduces Nissl bodies in the rat MCAO model”

• cites Wang et al., 2019 sourcePartly supported

  The knockdown results sections report larger infarcts, more brain swelling, and increased neuronal apoptosis in cold-saline-treated rats with MCAO. The Nissl-body finding is inconsistent: the results section says relative IOD increased, while the Discussion says it decreased. The experiments also concern rats receiving intracarotid cold saline infusion, a condition omitted from the claim. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

SGK1 is present in microglia, oligodendrocytes, and astrocytes.

“Currently, reports indicate that SGK1 is present in microglia (Inoue et al., 2016b), oligodendrocytes (Hinds et al., 2017), and astrocytes (Tertil et al., 2018).”

• cites Inoue et al., 2016bNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Hinds et al., 2017 sourceSupported
• cites Tertil et al., 2018 sourceSupported

May combine two claims.

EMD638683 inhibits SGK1 by blocking ATP binding, suppressing its phosphorylation activity.

“It inhibits SGK1 by blocking ATP binding, suppressing its phosphorylation activity”

• cites Elahi et al., 2021 sourcePartly supported

  The Results section (Figure 6 and the accompanying text; page unavailable) reports that EMD638683 inhibits SGK1 activity and reduces SGK1-mediated tau phosphorylation. Neither those passages nor the Discussion establish that it works by blocking ATP binding, so the claimed mechanism is unsupported. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

In Lafora disease, inhibiting SGK1 might be an effective therapeutic strategy to curb glycogen accumulation, suppress mTOR activity, and rectify autophagy defects.

“Inhibiting SGK1 might be an effective therapeutic strategy to curb glycogen accumulation, suppress mTOR activity, and rectify autophagy defects in Lafora disease”

• cites Singh et al., 2013 sourceSupported

May combine two claims.

SGK1 is involved in regulating ion channels and transport proteins, cell apoptosis, proliferation and differentiation, autophagy, and neuroinflammation in the neurological system.

“In the neurological system, SGK1 is involved in regulating ion channels and transport proteins (Lang et al., 2014; Lang et al., 2010b), cell apoptosis (Martin-Batista et al., 2021a), proliferation and differentiation (Anacker et al., 2013), autophagy (Matteoni et al., 2019), and neuroinflammation (Wu et al., 2024).”

• cites Lang et al., 2014 sourceSupported
• cites Martin-Batista et al., 2021aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites Wu et al., 2024Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Classified as probably not a substantial claim.

SGK1 has been extensively studied across a diverse array of neurological disorders.

“SGK1 has been extensively studied across a diverse array of neurological disorders”

May combine two claims.

The array of neurological disorders in which SGK1 has been studied includes neurodegenerative diseases (Alzheimer's disease, Huntington's disease, Parkinson's disease), brain injuries (cerebral ischemia, traumatic brain injury), psychiatric conditions (depression, drug addiction), and chronic neurological disorders such as epilepsy.

“This array includes neurodegenerative diseases (e.g., Alzheimer’s disease, Huntington’s disease and Parkinson’s disease), brain injuries (e.g., cerebral ischemia and traumatic brain injury), psychiatric conditions (e.g., depression and drug addiction), as well as chronic neurological disorders such as epilepsy.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The human SGK1 gene is located on chromosome 6 at 6q23, spans 148,867 bases, contains 14 coding exons, and encodes a 431-amino-acid protein of approximately 49 kDa.

“The SGK1 gene in the human genome is located on chromosome 6 at the 6q23 region, spans 148,867 bases, and contains 14 coding exons. It encodes the SGK1 protein, which comprises 431 amino acids and has a molecular mass of approximately 49 kDa”

• cites Waldegger et al., 1998 sourceNot checked — no full text of the source
• cites Zhao et al., 2007 sourceNot checked — no full text of the source

May combine two claims.

In the inactive form of SGK1, the αC helix typical in other structures is absent, and the segment corresponding to the C helix forms a β-strand stabilized by a short anti-parallel β-sheet from the N-terminal segment of the activation loop.

“In the inactive form of SGK1, the αC helix typical in other structures is absent. Instead, the segment corresponding to the C helix forms a β-strand. This strand is stabilized by a short anti-parallel β-sheet from the N-terminal segment of the activation loop”

• cites Zhao et al., 2007 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

SGK1 is emerging as an increasingly compelling therapeutic target across the spectrum of neurological disorders, supported by the availability of several effective agents.

“SGK1 is emerging as an increasingly compelling therapeutic target across the spectrum of neurological disorders, supported by the availability of several effective agents.”

• AssumptionRests on an assumption: Findings from animal models of neurological disorders are predictive of human disease.

May combine two claims.

In disease states, a deletion mutation in the SGK1 gene causing loss of the first 60 N-terminal amino acids prevents effective ubiquitination and degradation by the 26S proteasome, leading to abnormally high steady-state levels of mutated SGK1 protein.

“However, in disease states, a deletion mutation in the SGK1 gene resulting in the loss of the first 60 amino acids at the N-terminus prevents effective ubiquitination and subsequent degradation by the 26S proteasome. This effect leads to an abnormally high steady-state level of the mutated SGK1 protein”

• cites Brickley et al., 2002 sourceNot checked — no full text of the source

May combine two claims.

WNK1 activates SGK1, which in turn activates ENaC.

“WNK1 (With No Lysine −1) activates the SGK1, which, in turn, leads to the activation of the ENaC”

• cites Xu et al., 2005Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

The conclusions of many studies observing the prevalence and function of SGK1 in neurological disorders are contradictory, necessitating a review of SGK1 research within neurological disorders.

“However, the conclusions of many studies observing the prevalence and function of SGK1 in neurological disorders are contradictory, necessitating a review of the SGK1 research within neurological disorders.”

May combine two claims.

SGK1 regulates ion channels, membrane carriers, transcriptional factors or regulators, cellular enzymes, and neuronal excitability.

“It holds a crucial position in managing a variety of ion channels, membrane carriers, transcriptional factors or regulators, and cellular enzymes, as well as in controlling neuronal excitability”

• cites Lang et al., 2010aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

In many cell types, endogenous SGK1 is typically present at very low levels.

“It’s noteworthy that in many cell types, endogenous SGK1 is typically present at very low levels”

• cites Brickley et al., 2002 sourceNot checked — no full text of the source

May combine two claims.

SGK1 plays a role in enhancing memory formation and reducing Aβ production, highlighting its potential in treatment of Alzheimer's disease.

“An increasing number of studies indicate that SGK1 plays a role in enhancing memory formation and reducing the production of Aβ, highlighting its potential in the treatment of AD”

• cites Lian et al., 2020 sourceNot checked — no full text of the source
• cites Tyan et al., 2008 sourceNot checked — no full text of the source

May combine two claims.

Overexpression of SGK1 receptors in the dorsal hippocampus enhances memory, correlating with increased expression of SGK1 and mRNA of hippocampal glutamate receptor subunits GluA1 and GluA2.

“Overexpression of SGK1 receptors in the dorsal hippocampus enhances memory, which correlates with a significant increase in the expression of SGK1 and the mRNA of hippocampal glutamate receptor subunits GluA1 and GluA2”

• cites Lengel et al., 2022 sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

SGK1 is regulated by serum and glucocorticoid levels.

“As the name suggests, SGK1 is regulated by serum and glucocorticoid levels”

• cites Lang et al., 2009aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

SGK1 plays an important role in regulating ion transport and maintaining osmotic balance within the brain.

“These findings define the importance of SGK1’s role in regulating ion transport and maintaining osmotic balance within the brain.”

May combine two claims.

SGK1 upregulates PSD-95 expression in the hippocampus, facilitating LTP expression in hippocampal neurons.

“SGK1 upregulates the expression of postsynaptic density protein-95 (PSD-95) in the hippocampus, which facilitates the expression of LTP in hippocampal neurons”

• cites Ma et al., 2006Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Overexpression of SGK1 reverses spatial memory impairments and decreases production and deposition of Aβ in APP/PS1 mice.

“When overexpressed, SGK1 reverses spatial memory impairments, as well as decrease the production and deposition of Aβ.”

• cites Lian et al., 2020 sourceNot checked — no full text of the source

May combine two claims.

In human AD patients, SGK1 levels are not significantly different from age-matched controls, but there is a notable increase in phosphorylation of NDRG1, a specific target of SGK1.

“In human AD patients, the level of SGK1 is not significantly different from age-matched controls. Still, there is a notable increase in the phosphorylation of N-myc downstream-regulated gene family member 1 (NDRG1), a specific target of SGK1”

• cites Sahin et al., 2013 sourceNot checked — no full text of the source

May combine two claims.

SGK1 plays a pivotal role in progression and pathophysiology of Parkinson's disease, but inconsistency in results can be attributed to diversity of experimental models, dose-dependent effects, and variations in experimental methodologies.

“These studies underscore the pivotal role of SGK1 in the progression and pathophysiology of PD. However, the inconsistency in results can be attributed to factors such as the diversity of experimental models, dose-dependent effects, and variations in experimental methodologies.”

May combine two claims.

SGK1 is a potent antioxidant and has been implicated in pathogenesis of Huntington's disease.

“SGK1 is a potent antioxidant and has been implicated in the pathogenesis of HD”

• cites Ferrelli et al., 2015 sourceNot checked — no full text of the source
• cites Rangone et al., 2004 sourceNot checked — no full text of the source

May combine two claims.

Upregulation of SGK1 elevates levels of actin remodeling-related proteins Rictor, Rac1, Cdc42, and Profilin-1 in the hippocampus of AD mice, which may impact neuronal structure and function.

“Furthermore, upregulation of SGK1 elevates the levels of actin remodeling-related proteins, such as Rictor, Rac1, Cdc42, and Profilin-1 in the hippocampus of AD mice, which may impact the structure and function of neurons”

• cites Chen et al., 2012 sourceNot checked — no full text of the source
• cites Lian et al., 2020 sourceNot checked — no full text of the source

May combine two claims.

In an AD mouse model, significant myelin loss occurs alongside increased oligodendrogenesis and remyelination, indicating concurrent myelin degeneration and repair during AD progression.

“A recent study in an AD mouse model revealed significant myelin loss alongside increased oligodendrogenesis and remyelination, indicating concurrent myelin degeneration and repair during AD progression”

• cites Chen et al., 2021aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

SGK phosphorylates huntingtin protein at serine 421, and this phosphorylation can protect striatal neurons from toxicity of mutant huntingtin protein.

“Moreover, SGK phosphorylates huntingtin protein at serine 421, and this phosphorylation can protect striatal neurons from the toxicity of mutant huntingtin protein”

• cites Rangone et al., 2004 sourceNot checked — no full text of the source

May combine two claims.

Total SGK protein levels, encompassing SGK1 and SGK3, show an upregulation trend in brains of Huntington's disease patients, with concentration increasing as disease severity progresses.

“Total SGK protein levels, encompassing both SGK1 and SGK3, show an upregulation trend in the brains of HD patients, with the concentration increasing as the severity of the disease progresses”

• cites Rangone et al., 2004 sourceNot checked — no full text of the source

May combine two claims.

MPTP treatment upregulates SGK1 and DRP1 expression dose-dependently, triggering neuronal damage via the SGK1-FOXO3a pathway and causing oxidative stress and mitochondrial dysfunction.

“MPTP treatment upregulates SGK1 and DRP1 expression dose-dependently, triggering neuronal damage via the SGK1-FOXO3a pathway and causing oxidative stress and mitochondrial dysfunction”

• cites Li et al., 2019Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

In C2C12 cells, siRNA-mediated reduction of SGK1 leads to increased α-syn expression, aligning with findings from the MPTP-treated mouse model.

“In C2C12 cells, SGK1 was effectively reduced using siRNA, and the resulting inhibition of SGK1 led to an increased expression of α-syn, aligning with findings from the MPTP-treated mouse model”

• cites Heo et al., 2023 sourceNot checked — no full text of the source

May combine two claims.

In MPTP-induced PD mouse model, acupuncture stimulation maintains SGK1 expression at control levels, resulting in reduction of α-synuclein levels.

“Similarly, in the MPTP-induced PD mouse model, acupuncture stimulation maintained SGK1 expression at levels comparable to the control group, resulting in a reduction of α-synuclein levels”

• cites Yeo and Lim, 2019 sourceNot checked — no full text of the source

May combine two claims.

The increase in SGK1, through inhibition of GSK-3β/β-catenin pathway, ultimately suppresses caspase-3 activation, inhibiting neuronal apoptosis in TBI.

“The increase in SGK1, through the inhibition of the GSK-3β/β-catenin pathway, ultimately suppresses caspase-3 activation, inhibiting neuronal apoptosis in TBI”

• cites Wu et al., 2013Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Applying neuron-specific SGK1 knockdown ameliorated mitochondrial dysfunction, learning/memory, motor, and anxiety deficits following CA.

“Applying neuron-specific SGK1 knockdown ameliorated mitochondrial dysfunction, learning/memory, motor, and anxiety deficits following CA”

• cites Wu et al., 2024Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

SGK1 aids in suppressing neuroinflammation in TBI by GR signaling pathway and remyelination.

“Suggesting SGK1 aids in suppressing neuroinflammation in TBI by the GR signaling pathway and remyelination.”

May combine two claims.

In rats, SGK1 transcription levels are markedly induced in neuron and oligodendrocyte area following cortical injury, with significant elevation by day three and sustained high expression for up to 14 days.

“In rats, SGK1 transcription levels are markedly induced in the neuron and oligodendrocyte area following cortical injury, with significant elevation observed by day three and sustained high expression levels for up to 14 days”

• cites Imaizumi et al., 1994 sourceNot checked — no full text of the source

May combine two claims.

Administering an SGK1 inhibitor 30 minutes before arterial occlusion in brain results in significant reduction in infarct volume and improves NMDA currents and peak amplitudes in calcium-cultured neurons.

“Administering an SGK1 inhibitor 30 minutes before arterial occlusion in the brain similarly results in a significant reduction in infarct volume and improves NMDA currents and peak amplitudes in calcium-cultured neurons”

• cites Inoue et al., 2016aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Pre-CA intraventricular injection of an SGK1 inhibitor in rats mitigated cortical hypoperfusion and neuroinflammation following CA, and enhanced neuronal survival in hippocampal CA1 region.

“Pre-CA intraventricular injection of an SGK1 inhibitor in rats mitigated cortical hypoperfusion and neuroinflammation (evidenced by reduced Iba1 expression) following CA, and enhanced neuronal survival in the hippocampal CA1 region”

• cites Lee et al., 2020 sourceNot checked — no full text of the source

May combine two claims.

SGK1 mediates autophagy in mammals, and loss of SGK1 function exacerbates mitochondrial permeability transition pore-dependent hepatic ischemia/reperfusion injury.

“SGK1 mediates autophagy in mammals, and the loss of SGK1 function exacerbates mitochondrial permeability transition pore-dependent hepatic ischemia/reperfusion injury”

• cites Zhou et al., 2019Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

In epileptic mice, activation of SGK1 leads to decrease in pro-apoptotic Bim protein levels in hippocampus, while anti-apoptotic protein Bcl-xL is upregulated.

“In epileptic mice, activation of SGK1 leads to a decrease in pro-apoptotic Bim protein levels in the hippocampus, while anti-apoptotic protein Bcl-xL is upregulated”

• cites Martin-Batista et al., 2021aNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

SGK1 in brain regulates various ion channels, including those relevant to neurovascular coupling.

“SGK1 in the brain regulates various ion channels, including those relevant to neurovascular coupling.”

May combine two claims.

The phenotype of SGK1 knockout mice is mild and only becomes pronounced under challenging conditions.

“The phenotype of SGK1 knockout mice is mild and only becomes pronounced under challenging conditions”

• cites Lang et al., 2010bNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Classified as probably not a substantial claim.

The potential mechanisms of SGK1 in relation to neurological disorders, particularly its precise molecular targets and mechanisms, remain unclear.

“The potential mechanisms of SGK1 in relation to neurological disorders, particularly its precise molecular targets and mechanisms, remain unclear.”

Classified as probably not a substantial claim.

The complex role of SGK1 could be one of the reasons for inconsistent results about SGK1 in neurological disorders.

“The complex role of SGK1 could also be one of the reasons for inconsistent results about SGK1 in neurological disorders.”

Classified as probably not a substantial claim.

The variation in research outcomes is due to inconsistencies in pathological models, intervention agents, the timing of interventions, and other factors.

“the research outcomes vary due to inconsistencies in the pathological models, intervention agents, and the timing of interventions, among other factors”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

The role and targeting of SGK1 in various brain diseases continue to be controversial.

“the role and targeting of SGK1 in various brain diseases studied, including neurodegenerative conditions, brain injuries, and psychiatric disorders, continue to be controversial.”

Probably not a substantial claim: may not pass S2 (checkable).

SGK1 remains a viable target in the research of various brain disorders.

“Regardless, SGK1 remains a viable target in the research of various brain disorders.”

• AssumptionRests on an assumption: SGK1 has unique biological properties.

Classified as probably not a substantial claim. May combine two claims.

Whether SGK1 acts as a catalyst exacerbating DD symptoms or serves as a neuroprotective compensatory agent in DD remains unclear.

“whether SGK1 acts as a catalyst exacerbating DD symptoms or serves as a neuroprotective compensatory agent in DD remains unclear.”